ArticleCommunications medicine2025
Targeted genetic screening for identifying carrier status and early-onset disease risks in Chinese newborns.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Comprehensive Meta-Analytical Investigation into the Incidence of Neonatal Amino Acid Metabolic Disorders Across China.International journal of neonatal screening · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundExpanded newborn genetic screening can identify a wide range of inherited conditions early in life. However, the prevalence and distribution of pathogenic and likely pathogenic variants in large-scale cohorts remain underexplored in the Chinese population.
methodsWe screened 33,894 newborns using targeted sequencing of 465 genes associated with monogenic disorders. Variants were classified with locally optimized American College of Medical Genetics and Genomics guidelines, focusing on pathogenic and likely pathogenic variants. We analyzed cumulative carrier rates, disease-specific prevalence, and regional differences.
resultsHere we show that among 33,894 newborns, 16,687 (49.2%) carry at least one pathogenic/likely pathogenic variant. In total, 22,457 such alleles are detected across 427 (91.8%) genes. Detection rates are higher in the south (52.1%) than in the north (48.5%). On average, each newborn carries 0.7 variants. The most frequent genes (allele frequency >1%) include GJB2 (5.56%), PAH (1.41%), and SLC26A4 (1.30%). The cumulative predicted incidence of 57 inborn errors of metabolism included in newborn tandem mass spectrometry screening is 1/2,177, with PAH, MMACHC, SLC22A5, MMUT and SLC25A13 as the main contributors. Regional analysis reveales significant geographic variation, with three inborn errors of metabolism (e.g., methylmalonic aciduria, phenylketonuria) more common in the north, five disorders (e.g. G6PD deficiency, thalassemia) more common in the south.
conclusionsThis large-scale study highlights the utility of targeted genetic screening for identifying carrier status and early-onset disease risks in newborns. The findings provide a critical foundation for integrating genetic screening into routine newborn care and for optimizing public health strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.